会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • P38 INHIBITORS
    • P38抑制剂
    • WO2008114119A3
    • 2009-12-23
    • PCT/IB2008000633
    • 2008-03-18
    • CADILA PHARMACEUTICALS LTDMODI INDRAVADAN AMBALALGHOSH PRASANTA KUMARBHARDWAJ DEVESHDESAI NIRAV MKHAMAR BAKULESH MAFATLAL
    • MODI INDRAVADAN AMBALALGHOSH PRASANTA KUMARBHARDWAJ DEVESHDESAI NIRAV MKHAMAR BAKULESH MAFATLAL
    • A01N47/28A61K31/17
    • A61K35/74
    • The invention relates to novel p38 MAPK inhibitor which involves Mycobacterium w and/or its constituents in pharmaceutically acceptable carriers and their uses. Mycobacterium w and/or its constituents when administered to mammal results in p38 inhibition The inhibition is found to last more than 28 days. It is also found to induce inhibition of TNF-alfa. it suppresses cytokines in a pattern identical to Glucocorticoids. In transforms cells it also induces apoptosis. P38 mediated conditions include inflammation, cell differentiation, cell proliferation, cell inhibition, cell cycle regulation, anti-inflammatory reactions, immune modulation, vascularization, response to external stimuli and angiogenesis. The use of Mycobacterium w (Mw) and / or constituents of Mycobacterium w for inhibition of p38 protein kinase i.e. (i) to induce apoptosis in transformed cells (ii) for inhibition of TNF-alfa (iii) for inhibition of cytokines.
    • 本发明涉及新颖的p38MAPK抑制剂,其涉及在药学上可接受的载体中的分枝杆菌和/或其成分及其用途。 当对哺乳动物施用时,分枝杆菌w和/或其成分导致p38抑制。发现抑制持续超过28天。 还发现诱导TNF-α的抑制。 它以与糖皮质激素相似的模式抑制细胞因子。 在转化细胞时,它也诱导细胞凋亡。 P38介导的病症包括炎症,细胞分化,细胞增殖,细胞抑制,细胞周期调节,抗炎反应,免疫调节,血管化,对外部刺激的反应和血管生成。 使用分枝杆菌w(Mw)和/或组织分枝杆菌w来抑制p38蛋白激酶,即(i)诱导转化细胞凋亡(ii)抑制TNF-α(iii)抑制细胞因子。